ORMP Key Stats
|Revenue (Quarterly YoY Growth)||Upgrade|
|EPS Diluted (TTM)||-0.6027|
|EPS Diluted (Quarterly YoY Growth)||Upgrade|
|Net Income (TTM)||-5.696M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM)||Upgrade|
ORMP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Oramed Pharmaceuticals is down 16.75% over the last year vs S&P 500 Total Return up 17.29%, Achillion Pharmaceuticals up 350.7%, and Celladon up N/A.
Balance Sheet View Statement
Y-Ratings for ORMP
Portfolio Strategies Featuring ORMP
Did Oramed Pharmaceuticals make it into our Portfolio Strategies?
Start your YCharts membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Company Website: http://www.oramed.com
- IR Website: http://ir.oramed.com/phoenix.zhtml?c=180902&p=irol-irhome
- HQ Country: Israel
- HQ State/Province: N/A
- Incorporation Country: United States
- Incorporation State/Province: Delaware
- Est. Current Fiscal Quarter End: November 30, 2014
- Est. Current Fiscal Year End: August 31, 2015
- Last Fiscal Quarter End: August 31, 2014
- Last Fiscal Year End: August 31, 2014
- NAICS: Pharmaceutical Preparation Manufacturing
- NAICS Code: 325412
- NAICS Industry: Pharmaceutical and Medicine Manufacturing
- NAICS Sector: Manufacturing
Oramed Pharmaceuticals Inc is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet.
ORMP Excel Add-In Codes
- Name: =YCI("ORMP","name")
- Description: =YCI("ORMP","description")
- Sector: =YCI("ORMP","sector")
- Industry: =YCI("ORMP","industry")
- Est. Current Fiscal Year End: =YCI("ORMP","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.